0804 GMT - The results of AstraZeneca's upcoming cancer drug trial have the potential to drive consensus forecasts toward the drug maker's 2030 sales target of $80 billion, Berenberg analysts say in a note. The British pharma company expects positive key late-stage trial readouts for its breast cancer drug Datroway, label extensions for its breast cancer drug Enhertu and hypertension treatment baxdrostat. The company guides for high-single-digit revenue growth but should face headwinds from patent expiries, U.S. Medicare drug pricing reform and foreign currency effects, they say. AstraZeneca's share price is back on track after its 2025 outlook eased investor concerns about the prospects for its China business, which is hampered by ongoing corruption investigation against some of its employees. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
February 26, 2025 03:04 ET (08:04 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.